Press Release – No. 12 / 2024 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Zealand Pharma announces that ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 1050 ET – Zealand Pharma’s petrelintide shot has the ...

CEO Adam Steensberg emphasized 2024 as a transformational year for Zealand Pharma, highlighting significant clinical advancements in its obesity pipeline, particularly with petrelintide and ...

Company announcement – No. 4 / 2025 Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people ...

Zealand Pharma's petrelintide shot has the potential to reduce body weight by more than 15% in longer trials, analysts from Jefferies write in a note following data from a 16-week trial that ...

In one part of a Phase 1b study, petrelintide, which targets the amylin hormone, led to 8.6% weight loss at 16 weeks, more than the 1.7% weight loss among patients taking placebo, the Danish ...

Zealand Pharma is also eligible for development milestones of $1.2 billion, primarily linked to initiation of Phase 3 trials with petrelintide monotherapy, and sales-based milestones of $2.4 ...

SAN ANTONIO — Petrelintide, a novel once-weekly amylin analog, was well-tolerated in a cohort of healthy people with overweight or obesity, while conferring up to 8.6% weight loss at 16 weeks, a ...

Danish biotech company Zealand Pharma A/S ZLDPF has announced encouraging topline results from a Phase 1b multiple ascending dose (MAD) trial of its weight management drug, petrelintide. The trial ...

According to Zealand (OTCPK:ZLDPF), petrelintide led to an 8.6% average weight loss over 16 weeks at a high dose, whereas those who received a placebo witnessed a 1.7% average weight loss.

Combining petrelintide with Roche's dual GLP-1/GIP receptor agonist CT-388 will further strengthen Roche's pipeline in cardiovascular, renal, and metabolic (CVRM) diseases.